SeqOne Genomics Closes €20M Series A Funding

SeqOne logo

SeqOne Genomics, a provider of next-generation genomic analysis solutions for personalized medical care, has raised EUR20M through Series A funding.

Omnes, Merieux Equity Partners led the round, Elaia, and IRDI Capital Investissement participated.

The company plans to use the funds for international sales acceleration and to develop new collaborative genomic analysis tools that facilitate communication between different departments in the medical team in order to improve patient outcomes in hereditary and cancer.

Nicolas Philippe, Ph.D. is the co-founder and CEO of SeqOne Genomics. This cloud-based solution manages all aspects of genomic analysis, from raw data to final reports presented to clinicians. The company provides high-performance genomic analysis solutions to healthcare providers who treat patients with cancer, rare or hereditary conditions, and pharmaceutical companies that are developing new treatments. This solution combines advanced machine learning with GeniOS(TM), the company’s proprietary genomics operating system, to speed up turnaround times and reduce costs. It also provides actionable insights that can be used for personalized medicine.

SeqOne’s board will be closed with this round.

  • Sacha Loiseau (Ph.D., independent board member, and Chairman of Board)
  • Fabien Collangettes, Director at Omnes,
  • Yoann Bonnamour is an Investment Manager at Merieux equity Partners.
  • Marc Rougier, Partner at Elaia,
  • Nicolas Philippe, cofounder and CEO at SeqOne Genomics.
  • Jean-Marc Holder is the co-founder and chief strategy and innovation officer at SeqOne Genomics.

The company employs more than 40 people, who are mainly experts in genomic medicine and data science.

Get latest news from African Startup ecosystem

Latest stories

You might also like...